NOACs Show Lower Risk of Adverse Renal Outcomes in A - Fib
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
More News: Brain | Cancer & Oncology | Cardiology | Coumadin | Emergency Medicine | Endocrinology | Geriatrics | Heart | Internal Medicine | Neurology | Nurses | Nursing | Pathology | Pradaxa | Urology & Nephrology | Warfarin